E
Emmanuelle Le Page
Researcher at French Institute of Health and Medical Research
Publications - 25
Citations - 1316
Emmanuelle Le Page is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Multiple sclerosis & Mitoxantrone. The author has an hindex of 12, co-authored 25 publications receiving 1167 citations. Previous affiliations of Emmanuelle Le Page include University of Rennes.
Papers
More filters
Journal ArticleDOI
Evidence for a two-stage disability progression in multiple sclerosis
Emmanuelle Leray,J. Yaouanq,Emmanuelle Le Page,M. Coustans,David Laplaud,Joel Oger,Gilles Edan,Gilles Edan +7 more
TL;DR: The results indicated that the disability progression during Phase 2 was independent of that during Phase 1, demonstrating that multiple sclerosis disability progression follows a two-stage process, with a first stage probably dependant on focal inflammation and a second stage probably independent of current focal inflammation.
Journal ArticleDOI
Acute Fulminant Demyelinating Disease: A Descriptive Study of 60 Patients
Jérôme De Seze,Marc Debouverie,Hélène Zéphir,Christine Lebrun,Frédéric Blanc,Véronique Bourg,Sandrine Wiertlewski,Sophie Pittion,David Laplaud,Emmanuelle Le Page,Romain Deschamps,Philippe Cabre,Jean Pelletier,Irina Malikova,Pierre Clavelou,Valérie Jaillon,Gilles Defer,Pierre Labauge,Olivier Gout,Clotilde Boulay,Gilles Edan,Patrick Vermersch +21 more
TL;DR: This study found some differences concerning the risk of evolution to clinically definite MS after a first demyelinating episode suggestive of ADEM, and proposed criteria that should now be tested in a larger, prospective cohort study.
Journal ArticleDOI
Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients
Emmanuelle Le Page,Emmanuelle Leray,Gregory Taurin,M. Coustans,Jacques Chaperon,Sean Patrick Morrissey,Gilles Edan +6 more
TL;DR: Mitoxantrone monthly for 6 months as induction therapy followed by maintenance treatment showed sustained clinical benefit for up to 5 years with an acceptable adverse events profile in patients with aggressive relapsing–remitting MS.
Journal ArticleDOI
Switching From Natalizumab to Fingolimod in Multiple Sclerosis A French Prospective Study
Mikael Cohen,Elisabeth Maillart,Ayman Tourbah,Jérôme De Seze,Sandra Vukusic,David Brassat,Olivier Anne,Sandrine Wiertlewski,William Camu,Sylvie Courtois,Aurélie Ruet,Marc Debouverie,Emmanuelle Le Page,Olivier Casez,Olivier Heinzlef,Bruno Stankoff,Bertrand Bourre,Giovanni Castelnovo,Audrey Rico,Eric Berger,Jean-Philippe Camdessanché,Gilles Defer,Pierre Clavelou,Abdullatif Al Khedr,Hélène Zéphir,Agnès Fromont,Caroline Papeix,Bruno Brochet,Jean Pelletier,Christine Lebrun +29 more
TL;DR: In this study, switching from natalizumab to fingolimod was associated with a risk of MS reactivation during the washout period or shortly after fingolIMod initiation, and the occurrence of relapse during the WP was the only significant prognostic factor for relapse during fingolinod therapy.
Journal ArticleDOI
Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial
Emmanuelle Le Page,David Veillard,David Laplaud,Stéphanie Hamonic,R. Wardi,Christine Lebrun,Fabien Zagnoli,Sandrine Wiertlewski,Véronique Deburghgraeve,M. Coustans,Gilles Edan +10 more
TL;DR: Oral administration of high-dose methylprednisolone for 3 days was not inferior to intravenous administration for improvement of disability scores 1 month after treatment and had a similar safety profile.